secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decibel Therapeutics, Inc. (—)
CIK:        0001656536
Form:       8-K
Filed at:   2023-09-25T23:59:59+00:00
Accession:  0001193125-23-240971
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron completes acquisition of Decibel Therapeutics for $4.00/share plus CVR up to $3.50
--------------------------------------------------------------------------------

- Cash consideration of $4.00/share plus up to $3.50/share in contingent value rights (CVR) tied to DB-OTO milestones.
- Tender offer accepted 19,797,530 shares (~86.12% of outstanding); merger completed under DGCL Section 251(h).
- Shares to be delisted from Nasdaq; Form 25 will be filed; registration to be terminated.
- All pre-merger directors resigned; replaced by Nouhad Husseini as sole director; officers replaced by Regeneron appointees.
- CVR milestones: $2.00 per CVR on DB-OTO fifth patient dosing by Dec 31, 2024; $1.50 on Registration Enabling Trial initiation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1656536/000119312523240971/0001193125-23-240971-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1656536/000119312523240971/d535787d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-240971

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer